A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Protocol: 
AAAR3867
Phase: 
I

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Are you Eligible? (Inclusion Criteria)

- Do you have a confirmed solid tumor?

- Have you had treatment for your disease before? Or is there not a standard
treatment available for your disease?

- Does your cancer continue to grow? Can your cancer not be removed by
surgery?

- Are you 18 years of age or older?

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States